Cure HIV Reaches Out to Foundation Community to Fund LiSAVIOR

HILTON HEAD ISLAND, S.C., April 1 /PRNewswire/ -- Dr. Roger Kenneth
Hershline, PhD, MD, the CEO of Global Humanceuticals, Inc. and founder and
chairman of the not-for-profit public charity CureHIV.us, announces today that
he is reaching out to the funder community, including funding initiatives such
as the Grand Challenges in Global Health initiative. The monies would be used
to begin clinical studies of a new drug and treatment method, LiSAVIOR.
This unique new drug is also known as compound NIAID #11039 and has
received a patent from the United States with patent number 6,821,958 on
November 23, 2004. Also, the World International Patent Organization published
the International Application Number as PCT/US2005/039528 on November 5, 2006.
Dr. Hershline hosted Session V at the World AIDS Day Conference in China
from December 1 to December 3, 2006, to initially present LiSAVIOR.
The proposed roadblock to cure HIV is that current drug and vaccination
treatments do not treat the growth of HIV in the gastrointestinal tract. HIV
virus multiplies and mutates in the gastrointestinal tract and then is
reabsorbed into the blood. This process is known to occur when HIV infection
results from the use of contaminated needles or during sexual intercourse. The
gastrointestinal tract is comprised of the mouth and its structures, the
pharynx, the esophagus, the stomach, the small intestines, the large
intestines and the anus.
The proposed solution to overcome this roadblock is the oral clinical use
of LiSAVIOR, a drug that is an early stage HIV life cycle inhibitor. LiSAVIOR
blocks not only viral entry into cells but also cell-to-cell transfer of the
virus. LiSAVIOR is proposed to be used alone or with any known HIV drug and
vaccine therapy.
Pre-clinical efficacy testing of LiSAVIOR has shown that the effective
concentration of LiSAVIOR is found to be equivalent to diluting a 1% solution
of LiSAVIOR one million times. LiSAVIOR is a dry, palatable, non-toxic powder
that is stable at room temperature and humidity.
"I am thinking in terms of problem solving. Traditional commercial drug
design and projects funding from the NIH has completely ignored this approach
to date," stated Dr. Hershline. "I think we have to talk in terms of a cure
for HIV. I want to cure HIV and that is why my foundation is called
CureHIV.us," concluded Dr. Hershline.
Dr. Hershline is hopeful that the foundation community, including the
Grand Challenges in Global Health initiative, looks into the work and progress
that he has made towards solving this problem and fills the gap in funding.
Dr. Hershline has a doctorate degree in drug design and a medical degree.
Pre-clinical development of LiSAVIOR has been twenty years in the making.
Despite the critical need for such a unique and potentially lifesaving
invention, LiSAVIOR remains completely un-funded.
Interested parties can contact Dr. Roger Kenneth Hershline, PhD, MD, thru
CureHIV.us Headquarters by email: Roger@CureHIV.us, mail: P.O. Box 23467,
Hilton Head Is., SC, 29925, fax: +1-843-342-5924, phone: +1-843-342-5900.
Direct to Dr. Hershline: +1-843-683-3683.
Web site: http://www.curehiv.us
This release was issued through eReleases(TM). For more information,
visit http://www.ereleases.com.
SOURCE CureHIV.us

Dr. Roger Kenneth Hershline, PhD, MD, of CureHIV.us, +1-843-683-3683,
Roger@CureHIV.us